Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Date:7/24/2008

PITTSBURGH, July 24 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, August 6, 2008, at 10:30 a.m. ET to provide a review of the second quarter ended June 30, 2008. The company will release its financial results before the market opens August 6.

The dial-in number to access the August 6 call is 877-741-4241 or 719-325-4787 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 8142044.

To access a live webcast of the August 6 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
2. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
3. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
4. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
5. Mylan Wins Generic Prilosec(R) Patent Litigation
6. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
7. Mylan Announces Final FDA Approval for Zaleplon Capsules
8. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
9. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: